Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

Emerging Infectious Diseases

Volumn 7, Issue 2, 2001, Pages 327-332

  Tenover, Fred C ^a,c   Biddle, James W ^a   Lancaster, Michael V ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Bright Ideas   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; NETILMICIN; OXACILLIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONFERENCE PAPER; DILUTION; DISEASE TRANSMISSION; HOSPITAL INFECTION; INFECTION CONTROL; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 0035042571     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0702.010237     Document Type: Conference Paper

References (50)

1. Staphylococcus aureus infections
2. Epidemiology of community-acquired infection
3. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: Trends in microorganisms isolated and the value of anaerobic culture of blood
4. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
5. Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and prognosis
6. National survey of methicillin-resistant Staphylococcus aureus
7. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance
8. The epidemiology of intravenous vancomycin usage in a university hospital: A 10 year study
9. Vancomycin
10. Postoperative infections and antimicrobial prophylaxis
11. Historical yearly usage of vancomycin
12. Determinants of vancomycin use in adult intensive care units in 41 United States Hospitals
13. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
14. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997
15. VRSA, VISA, and GISA: The dilemma behind the name game
16. Intermediate vancomycin resistance in Staphylococcus aureus: A major threat or a minor inconvenience?
17. New resistance in Staphylococcus aureus
18. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
19. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Definition of the clinical antibacterial spectrum of activity
20. Breakpoints in in-vitro antibiotic susceptibility testing
21. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
22. Vancomycin-resistant Staphylococcus aureus
23. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
24. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany
25. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus
26. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area
27. Emergence of vancomycin resistance in Staphylococcus aureus: Epidemiology and clinical significance
28. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
29. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999
30. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
31. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin
32. Vancomycin-intermediate resistant Staphylococcus aureus in Scotland
33. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibility to vancomycin
34. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
35. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds
36. Reversion of glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates
37. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
38. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50
39. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus
40. Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals
41. Laboratory capacity to detect antimicrobial resistance, 1998
42. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis center in Denmark
43. Interim guideline for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
44. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
45. Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control
46. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci
47. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy
48. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haemotologic malignancies: A problem of increasing importance